Crosstree

What Crosstree does

Crosstree Capital Partners Inc. is a Tampa, Florida-based investment banking firm founded in 2003 that specializes exclusively in M&A advisory for the Health Sciences sector. The firm serves founders, investors (private equity and venture capital), and operators of pharma services, diagnostics and tools, and healthcare technology companies, providing investment banking advisory, strategic advisory and origination, and recapitalization services. Crosstree operates through its wholly-owned broker-dealer subsidiary, Crosstree Capital Securities LLC, which is registered with the SEC and is a member of FINRA and SIPC. There is no proprietary technology platform; the offering is a relationship-driven, human-capital-intensive advisory service.

Revenue is generated through transaction-based advisory fees on M&A, recapitalization, and strategic advisory mandates across the health sciences value chain, with no disclosed public pricing. The firm claims to execute more industry-specific transactions than competitors 10x its size and, per Industry Genome data, ranks No. 1 globally in Pharma Services M&A advisory and Top 10 in Pharma IT M&A. Crosstree supplements its advisory franchise with proprietary research products including monthly BlueBooks transaction reports, Deal Insights, Market Maps, Whitepapers, and Case Studies. Recent transaction activity (2024-2025) spans advisory mandates for Deep 6 AI (acquired by Tempus), Actigraph (acquired Biofourmis' Life Sciences business), Anju Software (acquired by Valsoft), IPeople (acquired by RLDatix), ROI Healthcare Solutions (acquired by Acuvance), and Sengenics (acquired by Standard BioTools), among others.

The firm is privately held with no disclosed parent company, external funding, or institutional investor ownership; ownership appears to be retained by founders and/or management. Crosstree employs 50+ Health Sciences-focused professionals (with firmographics indicating 11-50 employees, suggesting the broader headcount may include non-employee professionals or extended coverage teams) and operates exclusively through direct enterprise sales channels, leveraging senior banker relationships and industry expertise from its Tampa headquarters while serving clients globally.

Name

Crosstree

Legal name

Crosstree Capital Partners Inc.

Website

https://crosstreecapital.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Crosstree Capital Partners is a Tampa-based, Health Sciences-exclusive investment banking firm founded in 2003 that provides M&A advisory, strategic advisory, and recapitalization services to founders, investors, and operators in pharma services, diagnostics, and healthcare technology.

Ownership category

akta.pro rank

Product category

Investment Banking / M&A Advisory

NAICS

Investment Banking and Securities Intermediation (52315), Portfolio Management and Investment Advice (523940)

SIC

Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)

akta.pro primary industry

Cross-Border M&A Advisory (FSAEAGAH)

Keywords

• Health sciences M&A advisory
• Investment banking services
• Pharma services advisory
• Healthcare technology advisory
• Recapitalization advisory

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. M&A Advisory Services: Crosstree generates revenue through investment banking advisory fees for mergers and acquisitions, strategic advisory, and recapitalization services in the health sciences sector. Revenue is generated through transaction-based advisory fees.
2. Strategic Advisory & Origination Services: Beyond value creation, the firm provides strategic advisory and origination services to growth-oriented companies, aligning them with financial partners who share common strategic vision and growth objectives.
3. Recapitalization Services: Deep industry understanding allows Crosstree to align growth-oriented companies with financial partners who share common strategic vision and growth objectives through recapitalization transactions.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Crosstree is a global investment banking firm that exclusively serves the Health Sciences and Pharma Services industries. It provides M&A advisory, strategic advisory and origination, and recapitalization services to founders, investors, and operators, complemented by proprietary research publications (BlueBooks, Deal Insights, Market Maps, Whitepapers, Case Studies). The firm also operates a FINRA/SIPC member broker-dealer affiliate, Crosstree Capital Securities LLC, to execute securities transactions.

Product overview

Crosstree is an investment banking firm providing M&A advisory services for the Health Sciences industry. The company operates through three core service offerings: Investment Banking Services (M&A advisory), Strategic Advisory & Origination Services, and Recapitalization Services. Additionally, they publish proprietary research products including BlueBooks (monthly M&A transaction reports), Deal Insights, Market Maps, Whitepapers, and Case Studies covering Pharma Services, Diagnostics & Tools, and Healthcare Technology sectors. The firm serves founders, investors, and operators seeking to execute transactions in the health sciences space.

Differentiator

Problem solved

Functional benefit

Products and services

• Investment Banking Services (Health Sciences M&A Advisory) Global M&A advisory services for founders, investors, and operators in the Health Sciences sector, delivered by senior bankers with deep professional relationships and sector expertise across pharma services, diagnostics and tools, and healthcare technology.
• Strategic Advisory & Origination Services Strategic advisory and origination services that go beyond value creation to align growth-oriented health sciences companies with financial partners sharing common strategic vision and growth objectives.
• Recapitalization Services Recapitalization advisory that aligns growth-oriented health sciences companies with financial partners sharing common strategic vision and growth objectives.
• BlueBooks (Monthly Health Sciences M&A Research) Monthly reports providing comprehensive coverage of M&A, recapitalization, and growth financing transactions across Pharma Services, Diagnostics & Tools, and Healthcare Technology, including year-on-year comparisons and sub-segment coverage such as Drug Development, Supply Chain, Pharma Commerce, and Pharma Technology.
• Broker-Dealer Services (via Crosstree Capital Securities LLC) Securities transaction and broker-dealer capabilities delivered through Crosstree Capital Securities LLC, the firm's SEC-registered, FINRA- and SIPC-member broker-dealer affiliate, supporting execution of M&A and capital markets transactions.

Quantifiable outcome

• No. 1 ranking in Advisory for Pharma Services M&A globally
• +1 more outcomes

Named customers14 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Goldman Sachs Healthcare Investment Banking: Goldman Sachs' Healthcare Investment Banking group is a bulge-bracket leader in healthcare M&A, frequently appearing on the same league tables as Crosstree. Significantly larger scale and global reach make it a broad incumbent peer rather than a direct mid-market competitor.
• Lazard Healthcare: Lazard operates a global Healthcare M&A advisory practice within its broader investment banking franchise. While it competes with Crosstree on pharma services and diagnostics mandates, its multi-sector scope and larger scale place it as a broad incumbent peer.
• Jefferies Healthcare Group: Jefferies operates a large, dedicated healthcare investment banking group covering M&A advisory and capital markets across pharma services, biotech, medtech, and diagnostics. It is a direct head-to-head competitor to Crosstree in the health sciences M&A league tables, with greater scale and broader product capabilities.

Direct peers

• Guggenheim Healthcare Investment Banking: Guggenheim's Healthcare Investment Banking group advises on M&A and capital markets for pharma, medical technology, and life sciences clients. Comparable sector focus and middle-to-large deal profile make it a relevant peer competing for similar sponsor-driven mandates.
• Robert W. Baird Healthcare: Baird's Global Healthcare Investment Banking team serves pharma services, medical technology, and life sciences companies with M&A advisory and equity capital markets. Similar mid-market focus and sponsor client base position it as a relevant peer in health sciences M&A.
• Piper Sandler Healthcare: Piper Sandler runs a dedicated Healthcare Investment Banking franchise covering pharma services, diagnostics, life sciences tools, and digital health M&A. Mid-market deal sizes and sponsor client overlap make it a direct competitor in Crosstree's core arena.
• William Blair Healthcare: William Blair's Healthcare Investment Banking group serves pharma services, medical technology, and diagnostics companies with M&A advisory and capital raising. Comparable mid-market posture and sector specialization position it as a direct peer competing for the same founder-led and sponsor-backed mandates.
• Leerink Partners: Leerink is a healthcare-focused investment bank providing M&A advisory, equity research, and capital markets to life sciences and healthcare companies. Its exclusive sector focus and middle-market orientation make it one of the closest direct competitors to Crosstree in pharma services and health tech M&A.
• Lincoln International Healthcare: Lincoln International runs a dedicated Healthcare Group advising on M&A for pharma services, medical technology, and life sciences companies globally. Mid-market M&A focus and strong sponsor relationships make it a relevant direct peer in Crosstree's competitive set.
• Stifel Healthcare Investment Banking: Stifel's Healthcare Investment Banking group covers M&A advisory and capital markets for pharma services, life sciences tools, and medical technology. Mid-market focus and sector overlap make it a comparable peer competing for similar transactions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/crosstreecp

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crosstree